We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Google Releases AI Tool for Precision Medicine

By LabMedica International staff writers
Posted on 12 Dec 2017
Print article
Image: Google has announced the open source release of DeepVariant, a deep learning technology to reconstruct the true genome sequence from HTS data with significantly greater accuracy than previous classical methods (Photo courtesy of Google).
Image: Google has announced the open source release of DeepVariant, a deep learning technology to reconstruct the true genome sequence from HTS data with significantly greater accuracy than previous classical methods (Photo courtesy of Google).
Google LLC (Mountain View, CA, USA) has announced the open source release of DeepVariant, a deep learning technology to reconstruct the true genome sequence from high-throughput sequencing (HTS) data with significantly greater accuracy than previous classical methods. DeepVariant, which was developed after more than two years of research by the Google Brain team, in collaboration with Verily Life Sciences, transforms the task of variant calling, as this reconstruction problem is known in genomics, into an image classification problem well-suited to Google's existing technology and expertise. Within a year of its development, the deep learning model had won the 2016 PrecisionFDA Truth Challenge award for Highest SNP Performance, outperforming state-of-the-art methods. Since then, the Google Brain team has reduced the error rate by over 50%.

Google has released DeepVariant as open source software to encourage collaboration and accelerate its use in solving real world problems. It has partnered with Google Cloud Platform (GCP) to deploy DeepVariant workflows on GCP in two configurations optimized for low-cost and fast turnarounds using scalable GCP technologies, such as the Pipelines API. This paired set of releases provides a smooth ramp for users to explore and evaluate the capabilities of DeepVariant in their current compute environment, while providing a scalable, cloud-based solution to satisfy the needs of even the largest genomics datasets.

Google hopes that DeepVariant will leverage its computing infrastructure and machine learning expertise to better understand the genome as well as provide deep learning-based genomics tools to the community. The release of DeepVariant as open source software is part of its broader goal to apply Google technologies to healthcare and other scientific applications, and to make the results of these efforts broadly accessible.

Related Links:
Google

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.